Levodopa pharmacokinetic‐pharmacodynamic modeling and 6‐[¹⁸F]levodopa positron emission tomography in patients with Parkinson's disease

Abstract

Our findings show that key parameters of a PK-PD model of levodopa were in fairly close agreement with imaging of dopaminergic neurons by 6-[18F]levodopa PET. However, although PK-PD modeling of levodopa has been proven as a useful investigation of approaches aimed to restore dopaminergic deficits or to monitor disease progression, this modeling cannot serve as a pathomorphologic surrogate for the loss of striatal dopaminergic neurons.